Allied in the Fight against Viral Infectious Diseases

In order to accelerate our research and development efforts and advance product candidates, we collaborate with the following strategic partners:
US Army Medical Research Institute of Infectious Diseases (USAMRIID), USA: A leading authority in the field of infectious disease research and biodefense, USAMRIID has evaluated the inhibitory activity of TSG’s drug candidates against Zika, Ebola, and Marburg viruses; further evaluation against other mosquito-borne viruses are underway.
Public Health England - National Infection Service, UK: Evaluating the antiviral activity of TSG's drug candidate against Chikungunya virus across in vitro, in vivo, and ex vivo assay formats.
National Institute of Allergy and Infectious Diseases (NIAID), USA: A key component of the US National Institutes of Health (NIH), the NIAID is conducting in vitro, in vivo, and ex vivo antiviral assessments of TSG’s drug candidates against over 20 viruses.
WHO Collaborating Center for Research on Rabies Pathogenesis and Prevention, Thailand: Determining the in vivo effectiveness of TSG's drug candidates to treat Rabies virus infection in animal models.
Vanderbilt University, USA: Evaluating the in vitro and in vivo inhibitory activity of TSG's drug candidates against coronaviruses.
Ghent University, Belgium: Characterizing the effectiveness of TSG's drug candidates to cross the blood-brain barrier for treatment of viral infections in the brain.
Catholic University Leuven, Belgium: Evaluating the antiviral activity of TSG's drug candidates against multiple virus families across in vitro, in vivo, and ex vivo assay formats.